Lexeo Therapeutics, Inc. (LXEO)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$4.89+1.03%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · LXEO
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance dropped from the top half to the bottom half of its industry over the past month — the reason to own it has weakened.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
LXEO — earnings in line
Dated 2026-08-12
and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such a filing.
Why it matters: Updates on these programs will show progress in Lexeo's pipeline. This shows its ability to meet medical needs.
Watch forPositive updates or data releases for LX2020 and LX2022 in 2026.
Also watch forNo updates or negative data reported for LX2020 and LX2022 in 2026.
Why it matters: News on LX2006 is important for faster approval. Good news may help investors.
Supportive ifA press release says regulators accepted the study design for LX2006.
Worry ifRegulatory feedback shows big problems with the study design for LX2006.
Why it matters: The data update will show how well LX2020 works in PKP2 cardiomyopathy. This may affect future funding.
Supportive if12-month data shows good results for participants treated with LX2020.
Worry if12-month data shows no good results for participants treated with LX2020.
Why it matters: FDA feedback will guide the next steps for LX2006's path to approval. This could impact timelines.
Watch forFDA gives good feedback on the evidence strategy for LX2006.
Also watch forFDA has concerns about the evidence strategy for LX2006.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$263 on $10,000 · ±2.6% | How much price usually moves either way. |
| Bad day | $683 loss on $10,000 · 6.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,115 loss on $10,000 · 61.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: A drop in cash could hurt operations until 2028.
Worry ifCash and investments fall below $227.6 million.
Less concerning ifCash levels stabilize or increase above $227.6 million.
Why it matters: Enrollment progress will show how the trial is doing and if it meets data release timelines.
Supportive ifEnrollment meets or exceeds the goal of 13 participants in the SUNRISE-FA 2 trial.
Worry ifEnrollment stalls or falls short of the target participant number.
Why it matters: Interim data will show how well LX2006 works and its safety. This affects investor confidence and future funding.
Watch forThe interim clinical data is positive. It shows big improvements in mFARS scores.
Also watch forThe presentation shows no big improvements. There is also no negative safety data.
Why it matters: Topline data will show if LX2006 is effective for Friedreich ataxia. This is key for potential accelerated approval.
Supportive ifData shows a big increase in left ventricular mass index (LVMI) after 6 months.
Worry ifData shows no big change in LVMI compared to the control group.
Why it matters: FDA feedback will say if the trial design is okay for approval. This affects future studies.
Watch forFDA gives good feedback on the SUNRISE-FA 2 trial plan, allowing progress.
Also watch forFDA raises concerns about the trial protocol, delaying the study.